Michael Bryer-Ash, MD, FRCP

Abbreviated Biographical Sketch

Dr. Bryer-Ash earned his medical degree from the Middlesex Hospital Medical School (now University College London Medical School) of London University.  He completed a surgical internship at St. Andrew’s Hospital and a medical internship at St. George’s Hospital Medical School, both in London.  Dr. Bryer-Ash was a resident in internal medicine at the University of Chicago Hospitals and senior resident in internal medicine at Stanford University Medical Center, and he completed fellowships in endocrinology and metabolism both at Stanford University and the University of California, San Diego.

Board certified in both internal medicine (by the American Board of Internal Medicine, the Royal College of Physicians of Canada, and the Royal College of Physicians of London, U.K.) and endocrinology and metabolism (by the American Board of Internal Medicine and the Royal College of Physicians of Canada), Dr. Bryer-Ash has held faculty positions at the David Geffen School of Medicine at UCLA, the University of Tennessee, Memphis School of Medicine; Tulane University School of Medicine and the University of British Columbia.  He has received more than 20 scholarships, grants, and research awards from organizations in both the United States and Canada.

An author of more than 50 scientific articles in high-impact journals including Science, New England Journal of Medicine and Lancet, and more than 40 abstracts, Dr. Bryer-Ash has also served as a manuscript reviewer for leading medical journals in both the United States and Canada.

Dr. Bryer-Ash is a member of The American Diabetes Association, The Endocrine Society, The American Association for Clinical Endocrinology and the International Society for Clinical Densitometry. He is a Fellow of The Royal Colleges of Physicians of London and of Canada.

Clinical Interests

Dr. Bryer-Ash’s clinical interests include adult diabetes mellitus, thyroid disorders, metabolic bone disease and general clinical endocrinology.

Research Interests

Dr. Bryer-Ash's research interests include insulin signal transduction and the pathogenesis of insulin resistance, the metabolic syndrome and type 2 diabetes. His clinical and basic research programs have been funded by the NIH, Veterans Administration, American and Canadian Diabetes Associations, the Juvenile Diabetes Foundation and industry.

Education

Credentials

Hanley AJG, Wagenknecht LE, Norris JM, Bryer-Ash M, Chen YDI, Bergman R and Haffner SM. Insulin Resistance, Beta-cell Dysfunction, and Visceral Adiposity as Predictors of Incident Diabetes: The IRAS Family Study. Submitted to Diabetes – Oct 2008.

Wagenknecht LE, Scherzinger A, Stamm E, Hanley AJG, Norris JM, Chen YDI, Bryer-Ash M, Haffner SM and Rotter JI (2008) Correlates and Heritability of Nonalcoholic Fatty Liver Disease in a Minority Cohort. Obesity – in press.

Cheung D and Bryer-Ash M. (2008) Persistent Hypoglycemia in a Diabetic Patient Treated with Etanercept for Psoriasis. J Amer Acad  Dermatology – in press.

Palmer ND, Langefeld CD, Bryer-Ash M, Rotter JI, Taylor KD, Bowden DW. (2008) Association of the Kir6.2 E23K Variant with Reduced Acute Insulin Response in African Americans. J Clin Endocrinol Metab. 2008 Sep 16. [Epub ahead of print]

Foy CG, Hsu FC, Haffner SM, Norris JM, Rotter JI, Henkin LF, Bryer-Ash M, Chen YD, Wagenknecht LE. (2008) Visceral fat and prevalence of hypertension among African Americans and Hispanic Americans: findings from the IRAS family study. Am J Hypertens. 21:910-6. (Epub 2008 Jun 19).

Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, Florez JC. (2008) Diabetes Prevention Program Research Group. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 57:2503-10. (Epub 2008 Jun 10).

Bryer-Ash M. (2008) Discharge Planning for Patients with Established Diabetes and Newly Detected Hyperglycemia. In Hyperglycemia in Hospitalized Patients. (Moghissi E Ed. American College of Physicians, pp 27-28, June 2008.

Palmer ND, Goodarzi MO, Langefeld CD, Ziegler J, Norris JM, Haffner SM, Bryer-Ash M, Bergman RN, Wagenknecht LE, Taylor KD, Rotter JI and Bowden DW.  Quantitative Trait Analysis of T2D Susceptibility Loci Identified from Whole Genome Association Studies in the IRAS Family Study. Diabetes 57:1093-100. (Epub Feb 5 2008).

The ORIGIN Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 155:26-32, 2008.

Gallagher CJ, Langefeld CD, Gordon CJ, Campbell JK, Mychaleckyj JC, Bryer-Ash M, Rich SS, Bowden DW and Sale MM. Association of the estrogen receptor alpha gene with the metabolic syndrome and its component traits in African American families: The IRAS Family Study. Diabetes 56:2135-2141. (Epub: May 18 2007).

Hanley AJG, Bowden D, Wagenknecht LE, Balasubramanyam A, Langefeld CD, Saad MF, Rotter JI, Guo X, Chen Y-D I, Bryer-Ash M, Norris JM and Haffner SM. Correlates of Adiponectin in Hispanics and African Americans: The IRAS Family Study. J Clin Endocrinol Metab 92:2665-2671 (Epub: April 10 2007).

Huang D, Khoe M, Chung S, Befekadu M, Ilic D and Bryer-Ash M. Focal adhesion kinase promotes cell survival via NFκ-B and ERK signaling pathways. Am J Physiol (Cell Physiol) 292:C1339-1352. Epub 2006 Nov 29.

Tong Y, Huang D and Bryer-Ash M. Effects of globular adiponectin, glucose andfree fatty acid on AMPK and ACC phosphorylation in INS-1 cells. Journal of PekingUniversity (Health Sciences) 38:609-13, 2006.

Huang D, Khoe M, Ilic D and Bryer-Ash M. Reduced expression of focal adhesion kinase impairs insulin action in skeletal muscle cells. Endocrinology 147:3333-3343, 2006.

Liwanpo L, Tang R and Bryer-Ash M. Iodine-induced (Jod-Basedow) hyperthyroidism in the elderly: Case report and review of the literature.  Clinical Geriatrics 14:33-37, 2006.

Bryer-Ash M and Garber AJ. Point-Counterpoint. Point: Glycemic standards: The emperor finally has clothes. Diabetes Care 28:973-975, 2005.

Goodarzi M and Bryer-Ash M. Metformin: Its role in the expanding pharmacopoeia of antidiabetic agents. Diabetes, Obesity and Metabolism 7:654-665, 2005.